Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.74 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.74 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7440120 | 0.99 | PDE5A (0.74) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7440168 | 0.95 | PDE5A (0.73) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| Hydrochloric Acid SCHEMBL7439142 | 0.94 | PDE5A (0.73) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7278130 | 0.90 | PDE5A (0.75) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7436083 | 0.89 | PDE5A (0.74) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7280303 | 0.89 | PDE5A (0.68) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| Hydrochloric Acid SCHEMBL7437767 | 0.88 | PDE5A (0.74) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7440023 | 0.88 | PDE5A (0.68) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7441696 | 0.88 | PDE5A (0.58) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7277968 | 0.88 | PDE5A (0.59) | PDE5ATBXAS1PDE3BPDE3APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179152-A1 | Novel use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-1740183-B1 | NOVEL USE FOR PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2009-10-14 | — | — | EP | claimed |
| US-20070185114-A1 | Novel use for pde5 inhibitors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| JP-2006528229-A | — | — | 2006-12-14 | — | — | JP | claimed |
| US-20060148693-A1 | Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | claimed |
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | NYCOMED GMBH (DE) | 2006-05-04 | — | — | US | claimed |
| EP-1638567-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA Pharma AG (DE) | 2006-03-29 | — | — | EP | claimed |
| EP-1628682-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA Pharma AG (DE) | 2006-03-01 | — | — | EP | claimed |
| US-20050107394-A1 | for the treatment of respiratory failure in patients showing a mismatch of pulmonary ventilation and pulmonary perfusion; e.g. 3-ethyl-8-[2-(4-morpholinylmethyl)benzylamino]-2,3-dihydro-1H-imidazo[4,5-g]quinazoline-2-thione | GHOFRANI ARDESCHIR (DE) | 2005-05-19 | — | — | US | claimed |
| WO-2004110450-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA PHARMA AG (DE) | 2004-12-23 | — | — | WO | claimed |
| WO-2004103407-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-12-02 | — | — | WO | claimed |
| EP-1461022-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA Pharma AG (DE) | 2004-09-29 | — | — | EP | claimed |
| WO-2003051346-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | claimed |
| EP-3267986-B1 | PDE5 INHIBITORS FOR USE IN REDUCING RENAL CYST SIZE AND/OR PREVENTING RENAL CYST GROWTH | UNIV INDIANA RES & TECH CORP (US) | 2022-09-14 | — | — | EP | disclosed |
| US-10456404-B2 | Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180078559-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY COPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| WO-2004103407-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-12-02 | — | — | WO | disclosed |
| EP-1461022-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA Pharma AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003051346-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | PDE5A, PDE12, PDE4A | PDE5A 1/4885TBXAS1 1072/4885PDE3B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.